Patents Assigned to Daiichi Sankyo Company, Limited
-
Patent number: 12043658Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.Type: GrantFiled: November 21, 2022Date of Patent: July 23, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
-
Publication number: 20240239778Abstract: The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem.Type: ApplicationFiled: January 16, 2024Publication date: July 18, 2024Applicant: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Mitsuhiro Makino, Kaori Ito, Seiko Nagata, Makoto Hirasawa
-
Patent number: 12024566Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.Type: GrantFiled: July 9, 2019Date of Patent: July 2, 2024Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Takashi Matozaki, Mayumi Sue, Kensuke Nakamura, Chigusa Yoshimura
-
Patent number: 12024547Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.Type: GrantFiled: March 29, 2022Date of Patent: July 2, 2024Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
-
Publication number: 20240190961Abstract: Provided is a pharmaceutical composition for use in the treatment or prevention of cancer, etc. The present invention provides a pharmaceutical composition or a method for treating cancer, wherein an anti-GARP antibody and an immunomodulator are administered in combination.Type: ApplicationFiled: October 23, 2020Publication date: June 13, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shinko HAYASHI, Saori ISHIDA, Kazuki SATOH, Masato HATA
-
Patent number: 12006372Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.Type: GrantFiled: June 28, 2021Date of Patent: June 11, 2024Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kazuki Satoh, Kazuki Hirahara, Ichiro Watanabe, Masato Amano
-
Publication number: 20240182569Abstract: To provide a stable bispecific molecule. A Fab that specifically binds to CD3, the Fab comprising the following CDRH1 to 3 and CDRL1 to 3: CDRH1 consisting of the amino acid sequence represented by SEQ ID NO: 32; CDRH2 consisting of the amino acid sequence represented by SEQ ID NO: 33; CDRH3 consisting of the amino acid sequence represented by SEQ ID NO: 34; CDRL1 consisting of the amino acid sequence represented by SEQ ID NO: 35; CDRL2 consisting of the amino acid sequence represented by SEQ ID NO: 36; and CDRL3 consisting of the amino acid sequence represented by SEQ ID NO: 37.Type: ApplicationFiled: March 28, 2022Publication date: June 6, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makiko NAKAYAMA, Kensuke NAKAMURA, Shinji FURUZONO, Ryota MATSUMOTO
-
Patent number: 11999724Abstract: The present invention relates to a novel method for producing diarylpyridine derivatives, and the object of the present invention is to provide a novel, industrially useful method. The present inventors developed a novel method for synthesizing pyridine rings without using palladium, a strong base, or a high-temperature reaction. In particular, they successfully developed a method that can be used to synthesize iminium salts as intermediates, synthesize cyano compounds from these iminium salts, and cyclize the cyano compounds into pyridines under very mild reaction conditions.Type: GrantFiled: July 3, 2019Date of Patent: June 4, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Yuichi Aki, Fumihiko Toriyama, Natsuki Sakurai, Ai Kameda, Tomokazu Ogura
-
Patent number: 11993593Abstract: The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R1: a C1-C6 alkyl group or the like, R2: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R3, R3?: a C1-C6 alkyl group or the like].Type: GrantFiled: June 21, 2022Date of Patent: May 28, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Mitsuhiro Makino, Kaori Ito, Seiko Nagata, Makoto Hirasawa
-
Patent number: 11981686Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof, where each symbol in Formula (1) has the same definition as that described in the specification.Type: GrantFiled: January 23, 2020Date of Patent: May 14, 2024Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Junya Kawai, Osamu Iwamoto, Yuma Umezaki, Katsuyoshi Nakajima, Hiroyuki Tsuruoka, Keiji Saito, Nobuya Kurikawa, Natsumi Nishihama, Shinji Tanaka, Momoko Ogitani, Tomohiro Honda, Wataru Saitoh, Tsuyoshi Soneda, Nobuyuki Ohkawa
-
Publication number: 20240150472Abstract: The present invention provides a chimeric polypeptide receptor in which an extracellular region comprising an antigenic region capable of being bound by an anti-human nicotinic acetylcholine receptor ?1 subunit (nAChR?1) antibody, a transmembrane region, and an intracellular domain comprising an intracellular signaling domain are arranged in the presented order from the N-terminus towards the C-terminus, wherein an amino acid sequence of the antigenic region comprises the amino acid sequence as set forth in SEQ ID NO: 2 or an amino acid sequence derived from the amino acid sequence as set forth in SEQ ID NO: 2 by the substitution, deletion, insertion, and/or addition of one or several amino acids, a polynucleotide encoding the chimeric polypeptide receptor polypeptide, a cell expressing the chimeric polypeptide receptor, etc., which are useful in the treatment of myasthenia gravis.Type: ApplicationFiled: March 16, 2022Publication date: May 9, 2024Applicant: Daiichi Sankyo Company, LimitedInventors: Kazunori Yoshikiyo, Kazumichi Goto, Maki Tsujimoto, Chikako Nagasaki, Sayaka Yoshida, Hiroaki Tagaya
-
Publication number: 20240150309Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.Type: ApplicationFiled: November 3, 2023Publication date: May 9, 2024Applicant: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
-
Publication number: 20240150390Abstract: The purpose of the present invention is to provide a novel stereoselective method for preparing a cyclic dinucleotide derivative and a production intermediate therefor, which can be used for an antibody-immunostimulant conjugate. Also provided is a method for producing a cyclic dinucleotide-linker and an antibody-immunostimulant conjugate while using the above production method. Further provided is a method for preparing a cyclic dinucleotide derivative, the method including the step of subjecting a compound (I) and a compound (IV) to stereoselective condensation using an optically active phosphitylating agent (Rc-II) or (Sc-II).Type: ApplicationFiled: January 31, 2022Publication date: May 9, 2024Applicant: Daiichi Sankyo Company, LimitedInventors: Tomokazu OGURA, Takeshi NAKAYA, Hidekazu INOUE, Narumi ABE, Yuzo ABE, Tatsuya NAKAMURA, Yuko YAMAMOTO, Kohei SAKANISHI, Tatsuhiro SAKAMOTO, Satoshi NAKANE
-
Publication number: 20240139134Abstract: An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.Type: ApplicationFiled: December 21, 2023Publication date: May 2, 2024Applicant: Daiichi Sankyo Company, LimitedInventors: Naoki Tsuji, Masumi Ueno
-
Patent number: 11963974Abstract: The present invention provides a novel antisense oligonucleotide and a composition for preventing or treating glycogen storage disease type Ia. The present invention provides an antisense oligonucleotide which hybridizes with a pre-mRNA sequence derived from a region including at least one of a base at position 42911000, a base at position 42911004, and a base at position 42911005 in a base sequence of human chromosome 17 of GRCh38/hg38 and has activity to inhibit aberrant splicing of pre-mRNA of c.648G>T variant G6PC.Type: GrantFiled: March 9, 2018Date of Patent: April 23, 2024Assignees: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT, HIROSHIMA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Go Tajima, Satoshi Okada, Miyuki Tsumura
-
Patent number: 11958878Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).Type: GrantFiled: March 5, 2019Date of Patent: April 16, 2024Assignees: Daiichi Sankyo Company, Limited, Kobe Gakuin Educational FoundationInventors: Makoto Koizumi, Yoshiyuki Onishi, Takeshi Masuda, Mitsuhiro Iwamoto, Yukiko Sekiguchi, Kentaro Ito, Shinnosuke Tsuji, Masafumi Matsuo
-
Publication number: 20240115720Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Publication number: 20240115721Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Patent number: 11952423Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.Type: GrantFiled: May 16, 2023Date of Patent: April 9, 2024Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
-
Patent number: 11945882Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.Type: GrantFiled: August 30, 2018Date of Patent: April 2, 2024Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tatsuya Yamaguchi, Takashi Kouko, Shigeru Noguchi, Yohei Yamane, Fumikatsu Kondo, Takahiro Aoki, Tadahiro Takeda, Kohei Sakanishi, Hitoshi Sato, Tsuyoshi Ueda, Shinji Matuura, Kei Kurahashi, Yutaka Kitagawa, Tatsuya Nakamura